[HTML][HTML] Systemic therapies for metastatic castration-resistant prostate cancer: an updated review
K Hatano, N Nonomura - The World Journal of Men's Health, 2023 - ncbi.nlm.nih.gov
The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide
range of treatment options for patients with metastatic castration-resistant prostate cancer …
range of treatment options for patients with metastatic castration-resistant prostate cancer …
Technical and biological constraints on ctDNA-based genotyping
C Herberts, AW Wyatt - Trends in Cancer, 2021 - cell.com
Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely
collected tissue has hindered genomic stratification and precision oncology. Here, we …
collected tissue has hindered genomic stratification and precision oncology. Here, we …
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …
Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
No consensus strategies exist for prognosticating metastatic castration-resistant prostate
cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by …
cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by …
Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer
Background Multiple treatments are available for metastatic castration-resistant prostate
cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and …
cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and …
Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review
Background and objective Recently, research on treatment intensification has gathered
momentum, and three novel therapy combinations were approved for metastatic castration …
momentum, and three novel therapy combinations were approved for metastatic castration …
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation
Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …
Genetic and genomic testing for prostate cancer: beyond DNA repair
Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …